TREATMENT PATTERNS AMONG TYPE 2 DIABETES MELLITUS PATIENTS IN SAUDI ARABIA
Author(s)
Levy AR1, Szabo SM1, Osenenko KM1, Korol EE1, Qatami L2, Al Jaser S3, Al Saggabi A3, Al Suwaidan S3, Maclean R4, Donato BM5
1ICON Epidemiology, Vancouver, BC, Canada, 2Bristol-Myers Squibb Company, Dubai, United Arab Emirates, 3King Fahad National Guard Hospital, Riyadh, Saudi Arabia, 4Bristol-Myers Squibb Company, Plainsboro, NJ, USA, 5Bristol-Myers Squibb Company, Wallingford, CT, USA
METHODS: Charts from 455 adults with T2DM who visited the King Fahad National Guard Hospital from October 2009 to March 2010 (enrolment period) were systematically sampled until the target (n=250) was reached. Treatment data from enrolment to September 2011 were abstracted from subject charts. Treatment regimens, their frequency of use, and the number of switches (drug replacement/removal/addition) over the study period were calculated. Analyses were stratified by T2DM duration; data for those recently-diagnosed (<5 years; n=29) and with longstanding disease (≥20 years; n=67) are presented.
RESULTS: Forty-four percent of subjects were male; at enrolment, mean (SD) age was 61 (13) years, and mean T2DM duration was 11 (8) years. At enrolment, 42% of subjects had received prior insulin treatment (recently-diagnosed: 23%; longstanding disease: 52%). During the study period, the most common regimens were oral combination therapy (41%) and insulin+oral combination therapy (32%). Overall, 44% received any insulin therapy during the study period (recently-diagnosed: 25%; longstanding disease: 54%). By study end, 49% had received any prior insulin therapy (recently-diagnosed: 29%; longstanding disease: 58%). On average, T2DM subjects had 1.3 treatment switches over the period; little variation was seen by T2DM duration.
CONCLUSIONS: Although the frequency of insulin treatment was lower than reported in other studies from the region, treatment switches are indicative of attempts to improve T2DM control. Novel therapies may improve clinical outcomes among T2DM patients and this study provides valuable baseline data with which to compare the effectiveness of new T2DM treatments in Saudi Arabia.
Conference/Value in Health Info
Value in Health, Vol. 17, No. 7 (November 2014)
Code
PDB173
Topic
Health Service Delivery & Process of Care
Topic Subcategory
Treatment Patterns and Guidelines
Disease
Diabetes/Endocrine/Metabolic Disorders